BioBrit

BioBrit is a life sciences consulting and investment firm based in La Jolla, California. The firm specializes in providing strategic consulting services and investment opportunities in the life sciences sector, focusing on transforming businesses and bringing novel medicines and technologies to market. BioBrit offers expertise in business consulting, executive coaching, corporate strategic planning, financial modeling, and investment strategies.

The firm's investment approach encompasses various stages, including Seed, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, and Distressed investments. BioBrit primarily invests in the United States, with a particular emphasis on the Mid Atlantic region, from New York City to Washington D.C. The firm targets industries such as Pharmaceuticals and Biotechnology, with investment sizes ranging from $100,000 to $5 million.

BioBrit's Managing Member, Daniel M. Bradbury, brings over 40 years of experience in the life sciences industry. He has held leadership positions, including CEO of Amylin Pharmaceuticals and Executive Chairman of Equillium, Inc. Under his leadership, BioBrit has demonstrated a strong track record in the life sciences sector, focusing on investments that aim to maximize shareholder value and advance healthcare innovations.